| Hutchison Telecommunications (Australia) Limited (HTA) ORDINARY FULLY PAID |
Communication Services |
- |
Intention to Make Takeover Bid
|
22 May 2025 8:24AM |
$0.021 |
$0.031 |
risen by
47.62%
|
|
HTA - Price-sensitive ASX Announcement
Full Release
Key Points
- Hutchison Whampoa Limited has announced its intention to make a takeover bid for all shares in HTA that it does not already own.
- The offer will be made off-market at a specified cash price per share.
- The purpose of the takeover is to simplify the ownership structure and provide liquidity to shareholders.
- HTA has advised shareholders to take no immediate action in response to the offer.
- A formal bidder’s statement will be issued by Hutchison Whampoa subsidiary, and HTA will provide a response with further details.
- The document outlines the background, rationale, and process for the intended bid, with emphasis on next steps for shareholders.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Evolution Mining Limited (EVN) ORDINARY FULLY PAID |
Materials |
$25,748 |
Appointment of Chief Financial Officer
|
22 May 2025 8:23AM |
$8.670 |
$12.680 |
risen by
46.25%
|
|
| Hawsons Iron Ltd (HIO) ORDINARY FULLY PAID |
Materials |
$28 |
Project Update - Dry Processing Circuit
|
22 May 2025 8:23AM |
$0.014 |
$0.025 |
risen by
85.19%
|
|
HIO - Price-sensitive ASX Announcement
Full Release
Key Points
- Hawsons Iron Ltd released a project update on its dry processing circuit.
- Recent testwork and engineering have shown the dry circuit can significantly improve capital and operating costs.
- The dry circuit optimizes iron recovery and removes waste early in the process.
- This process reduces the environmental footprint by lowering water usage and tailings volume.
- The project's flowsheet optimization supports higher throughput and premium product quality.
- Further detailed engineering and testwork are underway prior to the final investment decision.
- The company emphasizes its commitment to sustainability and cost-effectiveness in project development.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Clearview Wealth Limited (CVW) ORDINARY FULLY PAID |
Financials |
$358 |
Update - Notification of buy-back - CVW
|
22 May 2025 8:22AM |
$0.490 |
$0.570 |
risen by
16.33%
|
|
| Dexus (DXS) FULLY PAID UNITS STAPLED SECURITIES |
Real Estate |
$7,486 |
Update on the Dexus Bloc interest in APAC
|
22 May 2025 8:22AM |
$7.220 |
$6.960 |
fallen by
3.60%
|
|
| Worley Limited (WOR) ORDINARY FULLY PAID |
Industrials |
$6,392 |
Update - Notification of buy-back - WOR
|
22 May 2025 8:21AM |
$13.140 |
$12.550 |
fallen by
4.49%
|
|
| Aruma Resources Limited (AAJ) ORDINARY FULLY PAID |
Materials |
$7 |
Drilling completed at Salmon Gums Gold Project
|
22 May 2025 8:21AM |
$0.011 |
$0.016 |
risen by
45.45%
|
|
AAJ - Price-sensitive ASX Announcement
Full Release
Key Points
- Aruma Resources Limited (ASX: AAJ) completed a 3,000-metre RC drilling program at the Salmon Gums Gold Project.
- The project is located in the Eastern Goldfields, Western Australia.
- Drilling targeted the Salmon Gums Shear Zone for gold mineralisation.
- 30 drill holes were completed in this phase of exploration.
- Initial field observations confirmed sulphide mineralisation and alteration zones.
- Assay results are pending and will determine the extent of gold mineralisation.
- The drilling program followed up on previous high-grade gold intersections.
- New drilling targets were defined through geochemical and structural analysis.
- The Salmon Gums Project is considered a strategic asset within Aruma's portfolio.
- Future exploration plans will be guided by the upcoming assay results.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Atlantic Lithium Limited (A11) ORDINARY FULLY PAID |
Materials |
$168 |
Spodumene Pegmatite Discovered at Agboville and Rubino
|
22 May 2025 8:21AM |
$0.135 |
$0.225 |
risen by
66.67%
|
|
A11 - Price-sensitive ASX Announcement
Full Release
Key Points
- Atlantic Lithium Limited reported new spodumene pegmatite discoveries at Agboville and Rubino licenses in Côte d’Ivoire.
- Exploration involved geological mapping, rock chip sampling, and reconnaissance across the license areas.
- Multiple spodumene-bearing pegmatite outcrops were identified, with high lithium oxide grades confirmed by assays.
- The findings support the company’s regional lithium exploration and development strategy.
- Further exploration, including drilling programs, is planned to determine the scale and resource potential of the discoveries.
- The announcement enhances the company’s lithium portfolio, which also includes the Ewoyaa Lithium Project in Ghana.
- Results indicate significant expansion potential in Côte d’Ivoire, aiming to build a multi-asset lithium business in West Africa.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Solvar Limited (SVR) ORDINARY FULLY PAID |
Financials |
$332 |
Update - Notification of buy-back - SVR
|
22 May 2025 8:21AM |
$1.695 |
$1.760 |
risen by
3.83%
|
|
| Shine Justice Ltd (SHJ) ORDINARY FULLY PAID |
Consumer Discretionary |
$125 |
Update - Notification of buy-back - SHJ
|
22 May 2025 8:21AM |
$0.690 |
$0.740 |
risen by
7.25%
|
|
| Brambles Limited (BXB) ORDINARY FULLY PAID |
Industrials |
$30,949 |
Update - Notification of buy-back - BXB
|
22 May 2025 8:21AM |
$21.920 |
$22.790 |
risen by
3.97%
|
|
| Zelira Therapeutics Limited (ZLD) ORDINARY FULLY PAID |
Health Care |
$5 |
Publication of ZLT-L-007 IRB Approved Observational Study
|
22 May 2025 8:21AM |
$0.495 |
$0.390 |
fallen by
21.21%
|
|
ZLD - Price-sensitive ASX Announcement
Full Release
Key Points
- Zelira Therapeutics Limited announced the publication of an IRB-approved observational study for ZLT-L-007.
- ZLT-L-007 is a proprietary cannabinoid formulation targeting chronic pain in musculoskeletal disorders.
- The study was published in the journal 'Medical Cannabis and Cannabinoids.'
- Patients reported significant improvements in pain, mood, and sleep after using ZLT-L-007.
- ZLT-L-007 was well-tolerated with no significant adverse effects observed.
- The study supports further clinical development and commercialization of ZLT-L-007.
- Zelira views this as an important milestone in developing cannabinoid-based medicines.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| L1 Long Short Fund Limited (LSF) ORDINARY FULLY PAID |
Financials |
$2,507 |
Net Tangible Asset Backing
|
22 May 2025 8:21AM |
$2.780 |
$3.960 |
risen by
42.45%
|
|
| Galileo Mining Ltd (GAL) ORDINARY FULLY PAID |
Materials |
$37 |
Fraser Range Project Drill Program Underway
|
22 May 2025 8:21AM |
$0.120 |
$0.185 |
risen by
54.17%
|
|
GAL - Price-sensitive ASX Announcement
Full Release
Key Points
- Galileo Mining Ltd has started a new drill program at the Fraser Range Project in Western Australia.
- The program is focused on nickel-copper mineralization targets identified by geophysical and geochemical data.
- Priority targets include the Callisto prospect and several adjacent anomalies.
- Technical background, including previous exploration results and geological modelling, inform the current drill targets.
- The drill campaign is intended to validate existing targets and potentially discover new zones of mineralization.
- Project timeline and anticipated next steps are outlined, with further drilling contingent on results.
- The announcement emphasizes Galileo Mining’s systematic exploration strategy and commitment to ongoing evaluation.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Lincoln Minerals Limited (LML) ORDINARY FULLY PAID |
Materials |
$39 |
Kookaburra Graphite Project Delivers 99.97% TGC purity
|
22 May 2025 8:21AM |
$0.005 |
$0.015 |
risen by
200%
|
|
LML - Price-sensitive ASX Announcement
Full Release
Key Points
- Lincoln Minerals Limited achieved 99.97% TGC purity from the Kookaburra Graphite Project.
- The purity level meets battery-grade standards required by energy storage and EV markets.
- Recent testwork confirmed the technical capability of the project to produce high-quality graphite.
- The announcement marks a significant step forward in project development and commercial readiness.
- LML intends to leverage this milestone for engagement with potential customers and partners.
- The company is focused on progressing project approvals and further technical studies.
- LML is positioning the Kookaburra Graphite Project as a significant supplier in the battery materials sector.
- Ongoing stakeholder engagement and regulatory processes are part of the company’s strategy.
- High-purity graphite is critical for lithium-ion battery applications.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Lincoln Minerals Limited (LML) ORDINARY FULLY PAID |
Materials |
$39 |
Minbrie Copper-Zinc Project Investor Webinar 28 May 2025
|
22 May 2025 8:21AM |
$0.005 |
$0.015 |
risen by
200%
|
|
| Neuren Pharmaceuticals Limited (NEU) ORDINARY FULLY PAID |
Health Care |
$2,395 |
Update - Notification of buy-back - NEU
|
22 May 2025 8:21AM |
$12.920 |
$18.910 |
risen by
46.36%
|
|
| Acusensus Limited (ACE) ORDINARY FULLY PAID |
Information Technology |
$272 |
Wilsons Rapid Insights Conference Presentation
|
22 May 2025 8:20AM |
$1.055 |
$1.680 |
risen by
59.24%
|
|
| Comms Group Ltd (CCG) ORDINARY FULLY PAID |
Communication Services |
$37 |
Entitlement Offer Booklet
|
22 May 2025 8:20AM |
$0.053 |
$0.068 |
risen by
28.30%
|
|
CCG - Price-sensitive ASX Announcement
Full Release
Key Points
- Entitlement Offer by Comms Group Ltd to raise up to $6 million at $0.015 per share.
- Offer is non-renounceable and available to eligible shareholders on a 1-for-3 basis.
- Funds will be used to strengthen the balance sheet, support growth strategies, and provide working capital.
- The offer is underwritten up to $3 million by KG Investments No 2 Pty Ltd.
- Detailed instructions for shareholders on how to participate or take no action.
- Key risks outlined include market, liquidity, dilution, and operational risks.
- Timetable includes offer opening, closing, and allotment dates.
- Directors and key management are participating in the offer.
- Disclosure of company structure, financial position, and strategic plans.
- Risks and disclaimers provided in accordance with ASX listing rules.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| G8 Education Limited (GEM) ORDINARY FULLY PAID |
Consumer Discretionary |
$529 |
Update - Notification of buy-back - GEM
|
22 May 2025 8:20AM |
$1.275 |
$0.685 |
fallen by
46.27%
|
|
| nanollose Limited (NC6) ORDINARY FULLY PAID |
Health Care |
$16 |
Change in substantial holding
|
22 May 2025 8:20AM |
$0.051 |
$0.049 |
fallen by
3.92%
|
|
| Argenica Therapeutics Limited (AGN) ORDINARY FULLY PAID |
Health Care |
$39 |
New US Patent for Surgical Stroke
|
22 May 2025 8:20AM |
$0.790 |
$0.305 |
fallen by
61.39%
|
|
AGN - Price-sensitive ASX Announcement
Full Release
Key Points
- Argenica Therapeutics Limited has been granted a new US patent for ARG-007 related to surgical stroke.
- The patent covers the use of ARG-007 to reduce brain injury during surgeries with risk of cerebral ischemia.
- This patent issuance strengthens Argenica’s intellectual property position in the US.
- ARG-007 is a neuroprotective peptide drug candidate developed by Argenica.
- The company aims to expand the clinical application of ARG-007 beyond acute ischemic stroke.
- The new patent supports Argenica’s strategy for clinical and commercial expansion.
- The announcement underscores the potential for ARG-007 in reducing neurological damage in surgical contexts.
- The patent is expected to aid in commercial partnerships and market exclusivity in the US.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| James Hardie Industries Plc (JHX) CHESS DEPOSITARY INTERESTS 1:1 |
Materials |
$13,252 |
Appendix 4G
|
22 May 2025 8:20AM |
$36.110 |
$30.790 |
fallen by
14.73%
|
|
| Waypoint REIT Limited (WPR) FULLY PAID ORDINARY/UNITS STAPLED SECURITIES |
Real Estate |
$1,658 |
Update - Notification of buy-back - WPR
|
22 May 2025 8:20AM |
$2.630 |
$2.540 |
fallen by
3.42%
|
|
| James Hardie Industries Plc (JHX) CHESS DEPOSITARY INTERESTS 1:1 |
Materials |
$13,252 |
Fiscal Year 2025 Irish Statutory Accounts
|
22 May 2025 8:20AM |
$36.110 |
$30.790 |
fallen by
14.73%
|
|
Call 1300 880 160
Start a chat
Schedule a call
